U.S. Markets close in 2 hrs 51 mins

AEMD: NCI Cancer Grant, FDA’s Real World Data

By Brian Marckx, CFA


Secondary Offering Nets $5.3M, AEMD Regains NASDAQ Compliance
On October 4th Aethlon (AEMD) closed on a secondary public offering of 5.4M shares at $1.10/share, with 100% warrant coverage (5yrs, $1.10 strike), for gross and net proceeds of $6.0M and $5.3M, respectively.  Pro forma for the financing, fiscal Q1 2018 (ending June 30, 2017) cash balance would equal approximately $5.6M.  

On August 1, 2017 AEMD received notice from NASDAQ that their stock would be de-listed from the exchange due to non-compliance of the > $35M market cap requirement.  The recent stock sale, however, allowed AEMD to regain NASDAQ under the alternative (5550b) requirement of having stockholder’s equity of at least $2.5M.  

Phase I NCI Grant for Isolation of Cancer-Related Exosomes

In mid-September AEMD announced that they scored a Phase I grant funded by the National Cancer Institute.  The contract, dubbed "Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes” is for $299,250.  The University of Pittsburgh and Massachusetts General Hospital (researchers at Mass General were part of the tumor exosomes study discussed below) will work under AEMD to complete the contract which involves evaluation of AEMD’s technology in the capture of circulating tumor-derived exosomes.    

Hemopurifier For Cancer Treatment…

As a reminder, Aethlon has long been considering the potential role that Hemopurifier might play in treating cancer given evidence of its ability to capture tumor-derived exosomes.  That interest has strengthened as of late given additional (published) evidence further supporting the role that circulating exosomes may play in tumor growth.  

This includes an article titled, "Extracellular Vesicles: Emerging Target for Cancer Therapy" published in the April 2014 issue of the journal, Trends in Molecular Medicine.  The article, written by researchers at Harvard Medical School, Massachusetts General Hospital and University of Oxford explores evidence that extracellular vesicles (i.e. - exosomes) play a key role in cancer development and progression and suppression of immune response.  As such, extracellular vesicles (EVs) have increasingly become targets for anticancer therapy.  This coincides with AEMD's cancer research and how Hemopurifier, via the removal of circulating cancer-secreted exosomes, could have utility in the treatment of cancer.  

The authors also believe that EVs may also increase the body's resistance to cancer drugs and hinder their effectiveness.  They further note that, while early evidence suggests that inhibition of EV biogenesis may have beneficial effects in the treatment of cancer, that a challenge has been to find therapies that can specifically target cancer-related EVs without affecting normal cell function.  The researchers specifically reference Hemopurifier as a potential therapy to overcome these challenges, noting that with the use of Hemopurifier might be possible to specifically capture tumour cell-derived EVs on an antibody-coated matrix during extracorporeal dialysis.  For example, in human epidermal growth factor receptor-2 (HER-2) overexpressing breast cancer, where HER-2-expressing EVs have been shown to interfere with therapy and are associated with tumour aggressiveness, anti-HER-2 antibodies could be used to remove HER-2-expressing EVs from circulation with the aim of improving therapeutic outcome.  In principal, this approach could be tailored for other tumour types, as long as the tumour cell-derived EVs are enriched for tumour-specific proteins. However, whether the level and duration of EV depletion
after ADAPT (i.e. - Hemopurifier) therapy would be sufficient to achieve a clinically relevant outcome remains to be

The authors note that their current understanding of EVs role in cancer development and progression is still in the relatively early stages and is based on data from in vitro experiments.  Their acknowledgement of Hemopurifier as potentially having utility in the treatment of cancer is also largely based on the supposition that removal of circulating EVs may be beneficial in interrupting the development and spread of tumors - which is still just a theory at this point. Nonetheless, we think this research does add meaningful credibility to Hemopurifier's potential role in cancer suppression and adds additional support to AEMD's research which indicates the same.  

In addition, the NCI grant is also an early, yet potentially substantive step towards additional acknowledgement of tumor-derived exosomes’ role in cancer  and validation of Hemopurifiers’ ability in capturing the substances.  

FDA Grants EAP Designation For Hemopurifier in Treatment of Life-Threatening Diseases
On September 12th AEMD announced that FDA approved AEMD's application seeking Expedited Access Pathway designation for their Hemopurifier with the following proposed indications for use; "The Hemopurifier is a single-use device indicated for the treatment of life-threatening highly glycosylated viruses that are not addressed with an approved treatment."  This implies a fairly broad indication given its non-specificity to a particular virus, disease or condition as well as the fact that many of the highly glycosylated viruses lack an effective therapy.   

As a refresher, viruses use glycosylation as a means to avoid detection by the body's immune system.  Highly glycosylated viruses, such as HIV, HCV, Ebola, West Nile and pandemic flu strains (among a host of others) have proven to be particularly resilient and difficult to treat.  The filter within the Hemopurifier contains galanthus nivalis agglutinin (GNA) which binds to the glycan shield of these viruses, thereby removing it from the bloodstream prior to the toxins infecting other cells or organs.  

While we had anticipated that FDA would approve the EAP pathway, confirmation of that is nonetheless a significant event given the benefits of the program.  Management noted during a presentation at BIO Investor Forum earlier this week that since receiving notice of EAP designation, the company has been in contact with FDA, including with the personnel that will be working directly with them.  AEMD expects to schedule an in-person meeting with FDA in the near-term.     

FDA Finalizes Guidance on Real-World Data For Regulatory Decision-Making
On August 31, 2017 FDA finalized their draft guidance (issued July 27, 2016) on the “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices”.  The document is available here (http://bit.ly/2xDKXG1).

While randomized, controlled studies (RCTs) will almost certainly remain the gold-standard for approving most Class III (i.e. high-risk) or other devices that are mandated to follow FDA’s PMA pathway, the agency has recently begun to embrace the idea of using “real world data” (RWD) and “real world evidence” (RWE) to make approval and other regulatory decisions.  In 2015 FDA approved more than eight new medical devices and expanded the label on several others through supporting RWD – this included several high-risk, implantable devices.

FDA’s recent move towards greater acceptance of RWD in decision-making has to do, in part, with the idea that traditional clinical trials are too rigid in some circumstances as well as the fact that “traditional clinical trial(s) may be impractical or excessively challenging to conduct” (as AEMD’s might be for highly virulent viruses).  That could mean that (for example), in lieu of a randomized clinical trial, the sponsor may be allowed to use an existing database or medical registry as the control arm for a pivotal study.

FDA’s recently appointed commissioner Dr. Scott Gottleib’s remarks to The National Academy of Sciences on September 19, 2017 provide some additional insight into the regulators’ thoughts towards greater application of RWD and RWE in their decision-making processes.  While the full text can be found here (http://bit.ly/2yJG4ex), some of the highlights include:  

➢ “The hierarchy of evidence is evolving as a consequence. This is the hierarchy that has long defined the reliability of clinical evidence, and puts the randomized, prospective, placebo controlled trial at the top of that pyramid. This pyramid has remained unchanged, even as our tools for collecting practical data have advanced; even as the constructs that fall underneath the fully randomized, prospective, placebo-controlled trial are expanding, and their usefulness for informing our decisions becoming more apparent; even as the reliability of other forms of evidence is increasing as the methodologies for evaluating different forms of data continue to improve. That includes RWE.”
➢ “FDA needs to think of itself as a curator of information. Not just an arbiter, where a single truth standard is secured to a fixed orthodoxy. The latter concept is increasingly at odds with the way decisions are being made by others who depend on reliable evidence to guide their paths, including doctors and health plans. FDA is often an important, independent evaluator of information.”
➢ “The fact is there’s often no single truth standard when it comes to the evidence used to support medical decisions. Clinical choices are made all the time, based on a mosaic of information of various precision and certainty. That continuum includes real world evidence, as well as the facts gleaned from rigorous and carefully fashioned trials...and a lot of evidence constructs in between.”
➢ “…there’s nothing in our statute or regulations that prevent FDA from using a broad range of informative sources of evidence. On the contrary, many of our statutory responsibilities boil down to one principal calculus: What do we know, and how do we balance benefits and risk based on the fullest possible information.”
➢ “For those who’d challenge the suitability of our effort to incorporate real world evidence into our regulatory model, I’d challenge you with the opposite intention: Should a product be marketed based on a data set that speaks to a limited and rigidly constructed circumstance, when the clinical use, and in turn the evidence we might have to evaluate the product, could have been far richer, far more diverse, and more informative?”
➢ “That means embracing the full continuum of evidence that informs their [i.e. novel medical devices] clinical use. We see this approach gaining more rapid and widespread acceptance when it comes to some medical products. But we need to continue to more widely advance this life cycle concept of regulation.”
Could RWD Facilitate and Help Define Hemopurifier’s FDA Pathway?...
As we have noted in our recent coverage of AEMD, we expect Hemopurifier will be required to follow a PMA pathway under the recently designated EAP program and expect this will require clinical trials.  Yet, as we have also noted, the next-steps towards validation are largely unknown given that it is not feasible to conduct clinical studies for targets such as highly virulent viruses or pandemic threats.  The benefits of EAP designation, particularly AEMD’s ability to have earlier and more significant involvement with regulators – can be of great help in designing an appropriate validation program.  

We do not know if the use of Real World Data is potentially on the table in designing a U.S. regulatory program for Hemopurifier or even if it is, if it can be of any benefit.  But given the (effective) impossibility of conducting, for example, an RCT in Ebola, yet the lack of any serious treatment-related adverse events in any human application of Hemopurifier, coupled with the complete dearth of any drug or device that can effectively treat many of these glycosylated viruses and evidence that Hemopurifier can capture these substances, it makes sense to us that RWD will be (at least) under consideration.  And if that is the case, it could help to define a feasible U.S. approval pathway.         

Production Capabilities Secured
Perhaps an indication of management’s expectations of eventual commercialization, earlier this week Aethlon announced a formal collaboration with iBio, Inc (IBIO), a plant-based biopharmaceuticals company, to provide (as-needed) large-scale production of the plant-derived lectin (a recombinant form of Galanthus nivalis agglutin, or GNA) housed within the Hemopurifier cartridge that captures circulating viruses from the blood.  

As a reminder, Aethlon had noted during their U.S. feasibility study that they had leveraged their contract with DARPA to fund current good manufacturing practice (cGMP) systems for the production of the Hemopurifier.  The DARPA grant included two manufacturing-specific milestones – the first of which AEMD completed during year-three of the contract and the other which they completed during year-four.   

AEMD’s recent press release mentions that they have completed a study with iBio, confirming their ability to produce GNA under cGMP.  Per iBio’s website, their CDMO development and manufacturing facility, located near Houston, is capable of growing over four million plants as “in process inventory”.  The large-capacity facility is also capable of meeting high production quotas which could be important, particularly in the event of high on-demand need such as, for example, if Hemopurifier was cleared for use as a countermeasure against certain pandemic outbreaks. 

See below for free access to our updated report on AEMD.


SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR and to view our disclaimer.

  • Business

    American Airlines Stock Has Gotten Clobbered. History Says It’s Time to Buy

    “Catching the falling knife” is supposed to be a stock market no-no. Momentum investors prefer to leave free-falling issues alone until they show signs of stabilizing, lest they keep right on falling. American Airlines stock closed up 2.8% on Monday, to $31.78. J.P. Morgan airline analyst Jamie Baker has made a study of what he calls the “down 30 in 30” trade: buying shares of airlines whose stocks fall 30% within 30 days.

  • Will U.S. Steel agreement with USW pave way for new EAF?
    American City Business Journals

    Will U.S. Steel agreement with USW pave way for new EAF?

    U.S. Steel Corp. (NYSE: X) and the United Steelworkers have reached a tentative agreement on a new labor deal that affect the revival of a major project in metro Birmingham. The new agreement would cover more than 14,000 workers at facilities around the nation, including Fairfield. Exact terms of the agreement haven't been disclosed, pending ratification, but representatives of U.S. Steel told the Birmingham Business Journal last week that the company's electric arc furnace project in Fairfield – which was put on the backburner in 2015 – was one of the operational enhancements that were part of the ongoing discussions.

  • Walmart is aggressively shifting away from its most legendary shopping format
    Yahoo Finance

    Walmart is aggressively shifting away from its most legendary shopping format

    Walmart (WMT) continues to kill off the American shopping creation it’s most known for, the massive supercenter that sells everything under one roof. With the U.S. market already having more than 3,500 Walmart supercenters and a focus by CEO Doug McMillon to increase spending on eCommerce and India, Walmart said Tuesday it will open a mere 10 supercenters in 2019. The company has reduced emphasis on the store format pioneered by founder Sam Walton – which could average a gargantuan 178,000 square feet – in recent years.

  • Where Will NVIDIA Be in 5 Years?
    Motley Fool

    Where Will NVIDIA Be in 5 Years?

    At one time, NVIDIA (NASDAQ: NVDA) floated under the radar in the technology sector. Its graphics processing units (GPUs) were then niche tech products that appealed mainly to graphic artists and hardcore PC gamers, but that all changed over the last

  • 3 Top Large-Cap Stocks to Buy in October
    Motley Fool

    3 Top Large-Cap Stocks to Buy in October

    If you're looking for high-quality large-cap stocks to add to your portfolio this month, three of our Motley Fool contributors have some ideas. Here's why you should consider Berkshire Hathaway (NYSE: BRK.B), Cisco Systems (NASDAQ: CSCO), and AT&T (NYSE: T). Tyler Crowe (Berkshire Hathaway): Perhaps one of the most ridiculous investment takes out there right now is that Berkshire Hathaway's immense cash pile isn't a good thing.

  • Even With $80 Oil, You Should Avoid These 3 Stocks
    Motley Fool

    Even With $80 Oil, You Should Avoid These 3 Stocks

    Three oil and gas stocks that truly stick out as companies with a "stay away" label are independent oil and gas producer SandRidge Energy (NYSE: SD), equipment and services provider Weatherford International (NYSE: WFT), and pipelines and logistics specialist Buckeye Partners (NYSE: BPL).

  • Brits Are All Making the Same Joke About the New Royal Baby

    Brits Are All Making the Same Joke About the New Royal Baby

    Meghan Markle, the Duchess of Sussex, is expecting her first child with Prince Harry. The news, announced Monday morning by Kensington Palace, has already been greeted by hundreds of messages of congratulations for the royal couple on social media. The U.K. is set to leave the European Union on March 29, exactly two years after Prime Minister Theresa May started the formal process for doing so by invoking Article 50 of the Lisbon Treaty.

  • These are the bad things about early retirement that no one talks about

    These are the bad things about early retirement that no one talks about

    For all the glamour of living an early retirement lifestyle, there are plenty of negatives I’ve come to discover since I permanently left my job in 2012. As a result, you’re repeatedly forced to will yourself into action.

  • Jamal Khashoggi was accidentally killed during interrogation: report
    Fox Business Videos

    Jamal Khashoggi was accidentally killed during interrogation: report

    Fox Business foreign policy analyst Walid Phares on the report that Saudi journalist Jamal Khashoggi was accidentally killed.

  • Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock
    Motley Fool

    Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock

    Gilead Sciences (NASDAQ: GILD) has clearly lost its luster as a growth stock over the last three years, thanks to a suite of setbacks for its oncology and hepatitis C franchises, as well as an increasingly competitive HIV marketplace. Gilead's stock, for instance, has woefully underperformed the broader biotech landscape during the past 36 months. With a price-to-sales ratio of 18.9 at present, Intercept's stock might not look like an outright bargain.

  • Under Armour HR chief Kerry Chandler heads to L.A. talent agency
    American City Business Journals

    Under Armour HR chief Kerry Chandler heads to L.A. talent agency

    Kerry Chandler has left her post as Under Armour Inc.'s chief human resources officer. Chandler departed he Baltimore sportswear maker to become chief human resources officer at Beverly Hills, California-based talent agency Endeavor. Prior to Under Armour (NYSE: UAA), Chander held senior executive human resources roles with Christie's International, the National Basketball Association, ESPN, IBM, and Motorola.

  • Goldman Sachs and Raymond James cut Netflix price target ahead of earnings
    Yahoo Finance Video

    Goldman Sachs and Raymond James cut Netflix price target ahead of earnings

    Netflix getting its price target slashed by both Goldman Sachs and Raymond James ahead of its highly expected earnings report tomorrow. Both firms are concerned that rising interest rates could pinch the company’s valuation.

  • Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla

    Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla

    The following article is part of a package of stories that MarketWatch is publishing to mark the start of full legalization of cannabis for adult use in Canada on Wednesday. Smith Falls, Ontario–based Canopy Growth Corp. made headlines and drove cannabis stocks to new heights over the summer when it announced that Corona brewer Constellation Brands Inc. was going to invest an additional $4 billion in the company. Billed by both companies as a strategic partnership, the additional $4 billion investment adds to the 9.9% stake that Constellation bought in October of last year and sets the company up to either be bought outright by Constellation — via warrants that could increase its stake to more than 50% — or continue to work with the beverage company to create a range of consumer-focused cannabis products that may one day appear in markets in dozens of countries.

  • 4 Reasons to Add Devon Energy (DVN) Stock to Your Portfolio

    4 Reasons to Add Devon Energy (DVN) Stock to Your Portfolio

    Estimates for Devon Energy Corporation DVN have been revised upward over the past 90 days, reflecting analysts’ confidence in the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings has moved 20.8% and 14.8% north to $1.63 & $3.10 per share

  • A Google self-driving car reportedly caused a crash in 2011 after a former engineer changed its code to drive where it wasn't supposed to (GOOG, GOOGL)
    Business Insider

    A Google self-driving car reportedly caused a crash in 2011 after a former engineer changed its code to drive where it wasn't supposed to (GOOG, GOOGL)

    Before Anthony Levandowski was accused of stealing trade secrets from Google sister company Waymo, he worked on Google's in-house self-driving car unit, nicknamed Project Chauffeur. Former Google executives claimed that Levandowski ignored safety concerns, including in one instance where he allegedly took a self-driving car on an off-limits route. While working at Google's Project Chauffeur, the self-driving car program that would later evolve into Waymo, Levandowski allegedly modified the car's software so it could be taken on routes that were previously off-limits.

  • JCPenney Stock: Do Analysts Foresee Any Upside?
    Market Realist

    JCPenney Stock: Do Analysts Foresee Any Upside?

    Can New CEO Bring JCPenney Back on Track? (Continued from Prior Part) Consensus “hold” rating Most analysts currently have a “hold” recommendation for JCPenney (JCP) stock. The mid-tier department store chain was rated a “hold” by 75%, or 12 out of 16

  • A Look at AT&T’s Dividends
    Market Realist

    A Look at AT&T’s Dividends

    What Investors Should Know about AT&T’s Growth Prospects (Continued from Prior Part) Shareholder returns Increasing capital returns to shareholders is one of AT&T’s (T) main priorities. In the second quarter, the company returned $3.1 billion to shareholders

  • Many U.S. mall owners say good riddance to Sears

    Many U.S. mall owners say good riddance to Sears

    The real estate investment trusts that own the malls and shopping centers where many Sears stores are anchor tenants have waited years for the retailer's demise to renovate the sites and boost rent, although redevelopment costs may strain some plans. Most large U.S. malls are controlled by REITs. In recent years, the REITs have cut their exposure to Sears Holdings Corp, which filed for Chapter 11 bankruptcy on Monday.

  • Business

    Jim Cramer Advises His Viewers On Cisco, Microsoft And More

    On CNBC's "Mad Money Lightning Round", Jim Cramer said Microsoft Corporation (NASDAQ: MSFT) can still be bought, but only a half of a position. United Technologies Corporation (NYSE: UTX) is going to be stuck until it buys Rockwell Collins, Inc. (NYSE

  • Apple Earnings: The Most Important Metric to Watch
    Motley Fool

    Apple Earnings: The Most Important Metric to Watch

    Apple (NASDAQ: AAPL) earnings are coming up -- and lots of investors will be watching. Scheduled for Nov. 1, the earnings release will give investors a better idea of how sustainable the company's reinvigorated growth rates are. Both Apple's revenue and earnings-per-share growth rates have accelerated recently.

  • Remembering Microsoft co-founder Paul Allen, dead at 65
    Yahoo Finance

    Remembering Microsoft co-founder Paul Allen, dead at 65

    Yahoo Finance’s Alexis Christoforous, Editor-in-chief Andy Serwer, Sibile Marcellus, Jared Blikre, Julia La Roche, Scott Gamm, Brian Sozzi and Heidi Chung discuss today’s top stories.  Today’s topics include: Roger McNamee reflects on the death of Paul

  • Finance

    Morgan Stanley: The stock sell-off is going to get worse

    The stock market is in the middle of a rolling bear market, says Morgan Stanley's Mike Wilson. "It's being caused by a drain in liquidity and peaking growth," Wilson says. The stock market sell-off is only going to get worse, predicts Morgan Stanley's chief U.S. equity strategist, Mike Wilson.

  • KMI, EPD, ETE, and OKE: Key Midstream Rating Updates
    Market Realist

    KMI, EPD, ETE, and OKE: Key Midstream Rating Updates

    MLPs Fell Last Week, Outperformed the Broader Markets (Continued from Prior Part) Credit Suisse updated its ratings Credit Suisse updated its ratings on several MLP and midstream stocks last week. Credit Suisse started coverage on Plains All American

  • World

    Saudi Arabia could hike oil prices over the Khashoggi case. Here's why it would backfire

    Fears are spreading that Saudi Arabia, amid the growing global outcry caused by the disappearance of Saudi journalist Jamal Khashoggi, may hit back at potential economic sanctions by weaponizing its oil dominance. A look at history and geopolitics suggests that while a Saudi-driven oil price spike would bring pain for much of the world, it would ultimately backfire on itself. Turkish officials allege that Khashoggi, a U.S. resident and Washington Post contributor, was murdered on orders of the Saudi government.

  • Better Buy: Western Digital Corporation vs. Intel Corporation
    Motley Fool

    Better Buy: Western Digital Corporation vs. Intel Corporation

    Western Digital (NASDAQ: WDC) and Intel (NASDAQ: INTC) are both mature tech companies that lead their respective industries. WD is the world's top maker of HDDs (hard disk drives), and Intel is the top manufacturer of CPUs for PCs and data centers. WD's stock tumbled 40% over the past six months, while Intel's stock slumped 15%.